**Core Concept**
The question is testing the knowledge of anesthetic induction agents in patients with bronchial asthma. The underlying principle is the selection of an agent that minimizes bronchospasm and maintains respiratory function.

**Why the Correct Answer is Right**
In patients with bronchial asthma, it is crucial to choose an anesthetic induction agent that does not trigger bronchospasm. **Ketamine** is a suitable choice because it has bronchodilatory properties, which help to relax the bronchial muscles and improve respiratory function. Unlike other induction agents, ketamine does not depress respiratory drive or cause significant bronchoconstriction.

**Why Each Wrong Option is Incorrect**
**Option A:** **Etomidate** is a short-acting intravenous anesthetic agent, but it can cause adrenal suppression and is not the preferred choice in asthma patients due to its potential to trigger bronchospasm.
**Option B:** **Propofol** is a widely used induction agent, but it can cause respiratory depression and is not ideal for patients with asthma due to its potential to trigger bronchospasm.
**Option C:** **Thiopental** is a barbiturate-based induction agent, but it can cause histamine release, leading to bronchospasm, making it a less desirable choice for patients with asthma.

**Clinical Pearl / High-Yield Fact**
In patients with bronchial asthma, it is essential to use an anesthetic induction agent that has bronchodilatory properties, such as ketamine, to minimize the risk of bronchospasm and maintain respiratory function.

**Correct Answer: C. Ketamine**